Chlorogenic acid targets STING to alleviate pressure overload-induced heart failure and myocardial fibrosis

Kai Huang1, Jing-Ling Xiao1, Jia-Yang Tang1

  • 1School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, PR China.

Insights

Chlorogenic acid (CGA) improves heart function and reduces fibrosis in chronic heart failure (CHF) by inhibiting STING and suppressing inflammation. This study highlights CGA as a potential therapeutic agent for CHF by targeting STING and CCR2+ macrophages.

Area of Science:

  • Cardiovascular Biology
  • Immunology
  • Pharmacology

Background:

  • Chronic heart failure (CHF) is a major cause of mortality, involving myocardial hypertrophy, fibrosis, and inflammation.
  • Chlorogenic acid (CGA) shows potential in improving cardiac function and reducing fibrosis, but its mechanism is not fully understood.

Purpose of the Study:

  • To elucidate the mechanism by which CGA improves cardiac function and reduces fibrosis in a mouse model of CHF.
  • To investigate the role of STING and CCR2+ macrophages in CGA's therapeutic effects.

Main Methods:

  • Transverse aortic constriction (TAC) mouse model of CHF.
  • Flow cytometry, echocardiography, Masson staining, Western blot, HE staining, immunofluorescence, molecular docking, and surface plasmon resonance (SPR).

Main Results:

  • CGA significantly improved left ventricular ejection fraction (EF) and reduced myocardial fibrosis in TAC mice.
  • CGA decreased cardiac neutrophils, macrophages (including CCR2+), and inflammatory markers by inhibiting STING and NF-κB p65 activation and pyroptosis.
  • CGA demonstrated stable binding to STING, suggesting it acts as a STING inhibitor.

Conclusions:

  • CGA ameliorates cardiac dysfunction and fibrosis in CHF by inhibiting STING, suppressing NF-κB-mediated pyroptosis, and reducing CCR2+ macrophage infiltration.
  • Targeting STING and CCR2+ macrophages presents a promising therapeutic strategy for CHF.
  • CGA is identified as a novel STING inhibitor with potential for CHF treatment.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
888
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
200
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
768
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
737
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.3K